Advertisement
VANI vs VTVT
Which Stock Would AI Choose? Vivani Medical (VANI) vs. vTv Therapeutics (VTVT) Stock Comparison
Key Takeaways
- Vivani Medical (VANI) is a clinical-stage biopharmaceutical company developing ultra long-acting, subdermal drug implants, led by a GLP-1 (glucagon-like peptide-1) implant pipeline targeting chronic weight management and type 2 diabetes.
- vTv Therapeutics (VTVT) is a late-stage biopharmaceutical company advancing cadisegliatin (TTP399), an oral, liver-selective glucokinase activator in a Phase 3 trial for type 1 diabetes.
- Both are small-cap, pre-commercialization biotech names with market capitalizations near $100 million, but their clinical stages, revenue profiles, and balance sheets differ meaningfully.
- VTVT generates episodic, license-driven revenue and holds a substantially larger cash balance, while VANI reports no product revenue and relies primarily on financing to fund its pipeline.
- Recent market activity has pressured both tickers, though the catalysts, volatility, and 52-week positioning of each remain distinct.
- Explore further on VANI Major News and VANI Today's Price Move, as well as VTVT Major News and VTVT Today's Price Move, for up-to-date coverage of each ticker.
- For a data-driven view of which tickers may be best positioned right now, explore Trending AI Robots.
Introduction
Investors evaluating small-cap biotechnology often weigh clinical progress, balance-sheet strength, and near-term catalysts against elevated volatility and binary risk. This stock comparison examines two development-stage healthcare companies trading on the Nasdaq Capital Market: VANI, a clinical-stage drug-delivery innovator, and VTVT, a late-stage metabolic-disease developer. Both address large, chronic-disease markets, yet their business models, financing profiles, and stages of pipeline advancement differ considerably. The relative performance and market positioning of these two names may be especially relevant for traders and investors focused on biotech catalysts, cash runways, and risk-adjusted momentum.
VANI Overview and Recent Performance
VANI is Vivani Medical, Inc., a clinical-stage biopharmaceutical company developing miniature, ultra long-acting subdermal drug implants built on its proprietary NanoPortal technology. The platform is designed to deliver medicines at a near-constant rate over extended periods, with candidates targeting chronic weight management and type 2 diabetes, including an exenatide-based GLP-1 implant and a semaglutide-based implant program.
As a pre-revenue company, Vivani reports no product sales, and its financial model depends on financing and collaboration activity to advance its pipeline. Recent market activity has been characterized by downward pressure, with the stock trading near the lower portion of its 52-week range and showing a double-digit percentage decline over recent weeks. Sentiment has been shaped by the broader environment for early-stage, pre-commercial biotech names, where investors weigh long-term platform potential against the absence of near-term revenue and the capital required to reach later-stage clinical milestones.
VTVT Overview and Recent Performance
VTVT is vTv Therapeutics Inc., a late-stage biopharmaceutical company focused on oral, small-molecule drug candidates for diabetes and other chronic diseases. Its lead program, cadisegliatin (TTP399), is a liver-selective glucokinase activator in a Phase 3 clinical trial (CATT1) as a potential adjunctive therapy to insulin for type 1 diabetes.
Unlike Vivani, vTv has reported license-driven revenue in recent quarters, including a $20 million upfront payment from an amended agreement with Newsoara Biopharma for its HPP737 program, with additional milestone and royalty potential. This activity strengthened the company's cash position, which stood at approximately $86 million at mid-2026. In recent weeks, however, the stock has pulled back from earlier highs, and its price remains well below the top of its 52-week range. Investor attention continues to center on the pace of Phase 3 enrollment, the anticipated topline data readout, and the company's cash runway.
Trending AI Robots
Tickeron maintains a dedicated Trending AI Robots page that curates a selection of AI-driven trading bots from its broader platform. Tickeron offers hundreds of AI trading bots that collectively monitor and trade thousands of different tickers; however, only the best-performing and most suitable bots for current market conditions earn a place in the Trending AI Robots section. Each bot operates with its own trading style, strategy, timeframe, performance statistics, and set of tickers it follows, meaning no two bots are alike. This curated list is designed to help users quickly identify the strategies that are currently resonating with market dynamics. To explore the latest selections and performance data, visit the Trending AI Robots page.
Head-to-Head Comparison
Although both companies operate in healthcare and are pre-commercialization, their profiles diverge in several important ways. In terms of business model, VTVT is further along the development curve with a Phase 3 program and has demonstrated an ability to generate non-dilutive, license-driven revenue. VANI, by contrast, is earlier-stage with a differentiated drug-delivery platform but no revenue to date.
On growth drivers, vTv's valuation is closely tied to cadisegliatin trial milestones and partnering economics, while Vivani's is anchored to the long-term promise of its implant platform in the highly competitive GLP-1 space. Risk factors also differ: vTv faces binary Phase 3 outcome risk, whereas Vivani faces earlier-stage clinical risk plus financing risk as a pre-revenue company. In terms of balance-sheet positioning, vTv's larger cash balance and recent licensing proceeds provide a comparatively longer runway, while Vivani carries a more modest balance sheet. On recent momentum and market sentiment, both stocks have weakened in recent weeks, reflecting broader caution toward speculative biotech names and idiosyncratic catalysts rather than a single shared driver.
Tickeron AI Verdict
Based on observable factors such as clinical-stage maturity, balance-sheet strength, and the presence of nearer-term catalysts, Tickeron's AI would currently lean toward VTVT. The company's later-stage pipeline, demonstrated license-driven revenue, and larger cash runway offer comparatively greater trend consistency and stability for an algorithmic framework. That said, this is a probabilistic assessment rather than a definitive call: VANI retains meaningful long-term optionality through its differentiated implant platform, and either name could experience sharp sentiment shifts tied to clinical data or financing developments. The relative positioning of both tickers may evolve quickly, underscoring the value of continuous, data-driven monitoring.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is VANI is a Hold and VTVT is a Hold.
Momentum Indicator for VANI turns positive, indicating new upward trend
VANI saw its Momentum Indicator move above the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 92 similar instances where the indicator turned positive. In 76 of the 92 cases, the stock moved higher in the following days. The odds of a move higher are at 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where VANI's RSI Oscillator exited the oversold zone, 20 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 66 cases where VANI's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Moving Average Convergence Divergence (MACD) for VANI just turned positive on November 09, 2026. Looking at past instances where VANI's MACD turned positive, the stock continued to rise in 40 of 51 cases over the following month. The odds of a continued upward trend are 78%.
Following a +7.48% 3-day Advance, the price is estimated to grow further. Considering data from situations where VANI advanced for three days, in 156 of 208 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
VANI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 50-day moving average for VANI moved below the 200-day moving average on October 29, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VANI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for VANI entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.089) is normal, around the industry mean (3.498). P/E Ratio (-2.972) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. VANI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VANI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Momentum Indicator for VTVT turns negative, indicating new downward trend
VTVT saw its Momentum Indicator move below the 0 level on October 12, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 84 similar instances where the indicator turned negative. In 75 of the 84 cases, the stock moved further down in the following days. The odds of a decline are at 89%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for VTVT turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 44 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VTVT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for VTVT entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where VTVT advanced for three days, in 221 of 264 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
VTVT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.057) is normal, around the industry mean (3.498). P/E Ratio (-33.919) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (10.331) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. VTVT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VTVT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
VANI | VTVT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 2 | 62 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 68 Overvalued | 5 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 94 | |
PRICE GROWTH RATING 1..100 | 72 | 83 | |
P/E GROWTH RATING 1..100 | 21 | 13 | |
SEASONALITY SCORE 1..100 | 85 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
VTVT's Valuation (5) in the Biotechnology industry is somewhat better than the same rating for VANI (68) in the null industry. This means that VTVT’s stock grew somewhat faster than VANI’s over the last 12 months.
VTVT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as VANI (100) in the null industry. This means that VTVT’s stock grew similarly to VANI’s over the last 12 months.
VTVT's SMR Rating (94) in the Biotechnology industry is in the same range as VANI (100) in the null industry. This means that VTVT’s stock grew similarly to VANI’s over the last 12 months.
VANI's Price Growth Rating (72) in the null industry is in the same range as VTVT (83) in the Biotechnology industry. This means that VANI’s stock grew similarly to VTVT’s over the last 12 months.
VTVT's P/E Growth Rating (13) in the Biotechnology industry is in the same range as VANI (21) in the null industry. This means that VTVT’s stock grew similarly to VANI’s over the last 12 months.
| VANI | VTVT | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 80% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 74% | 2 days ago 85% |
| Momentum ODDS (%) | 2 days ago 83% | 2 days ago 89% |
| MACD ODDS (%) | 2 days ago 78% | 2 days ago 85% |
| TrendWeek ODDS (%) | 2 days ago 75% | 2 days ago 89% |
| TrendMonth ODDS (%) | 2 days ago 81% | 2 days ago 88% |
| Advances ODDS (%) | 2 days ago 75% | 23 days ago 84% |
| Declines ODDS (%) | 27 days ago 85% | 6 days ago 88% |
| BollingerBands ODDS (%) | 2 days ago 79% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 84% | 2 days ago 87% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
VANI’s FA Score shows that 1 FA rating(s) are green while VTVT’s FA Score has 2 green FA rating(s).
- VANI’s FA Score: 1 green, 4 red.
- VTVT’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
VANI’s TA Score shows that 6 TA indicator(s) are bullish while VTVT’s TA Score has 4 bullish TA indicator(s).
- VANI’s TA Score: 6 bullish, 3 bearish.
- VTVT’s TA Score: 4 bullish, 4 bearish.
Price Growth
VANI (@Biotechnology) experienced а +9.52% price change this week, while VTVT (@Biotechnology) price change was -10.83% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
VANI is expected to report earnings on Nov 12, 2026.
VTVT is expected to report earnings on Mar 17, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
VANI and
Correlation & Price change
A.I.dvisor indicates that over the last year, VANI has been loosely correlated with VTVT. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if VANI jumps, then VTVT could also see price increases.
| Ticker / NAME | Correlation To VANI | 1D Price Change % | ||
|---|---|---|---|---|
| VANI | 100% | +2.22% | ||
| VTVT - VANI | 60% Loosely correlated | -0.85% | ||
| AZR - VANI | 37% Loosely correlated | +0.27% | ||
| NKTX - VANI | 37% Loosely correlated | -15.09% | ||
| AXSM - VANI | 36% Loosely correlated | +5.23% | ||
| SCNI - VANI | 34% Loosely correlated | +7.03% | ||
More | ||||
VTVT and
Correlation & Price change
A.I.dvisor indicates that over the last year, VTVT has been loosely correlated with VANI. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if VTVT jumps, then VANI could also see price increases.
| Ticker / NAME | Correlation To VTVT | 1D Price Change % | ||
|---|---|---|---|---|
| VTVT | 100% | -0.85% | ||
| VANI - VTVT | 59% Loosely correlated | +2.22% | ||
| CORT - VTVT | 49% Loosely correlated | -2.23% | ||
| NKTX - VTVT | 35% Loosely correlated | -15.09% | ||
| IMTX - VTVT | 34% Loosely correlated | -0.16% | ||
| CMND - VTVT | 34% Loosely correlated | -1.10% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| DJTU | 2.03 | 0.21 | +11.54% |
| T-REX 2X Long DJT Daily Target ETF (DJTU) | |||
| XLSI | 23.93 | 0.03 | +0.15% |
| State Street Consumer Staples Select Sector SPDR Premium Income ETF (XLSI) | |||
| FUND | 9.65 | N/A | N/A |
| Sprott Focus Trust | |||
| OAKI | 27.54 | -0.12 | -0.45% |
| Oakmark International Large Cap ETF (OAKI) | |||
| XHB | 103.17 | -2.79 | -2.63% |
| State Street SPDR S&P Homebuilders ETF (XHB) | |||